生物制剂治疗炎症性肠病专家建议意见

Consensus on biological agents in treating patients with inflammatory bowel disease

生物制剂在炎症性肠病(IBD)治疗中的应用越来越广泛。随着被批准应用的种类逐渐增多,如何合理、有效、安全地使用各种生物制剂是临床医师面临的新挑战。为了更好地指导我国IBD生物制剂的规范化使用,中国炎症性肠病诊疗质控评估中心联合中华医学会消化病学分会炎症性肠病学组共同组织我国相关领域多名专家对生物制剂治疗IBD的适应证、禁忌证、疗效证据、用药前机会性感染疾病筛查和预防、使用方法、疗效监测、特殊人群使用和安全性等多方面进行讨论,最终达成共识意见,以期为IBD生物制剂的规范化使用提供指导。

Biological agents have been increasingly used in the treatment of inflammatory bowel disease(IBD)in China.As the types of biologics and approved indications gradually increase,the rationale,effective and safe use of various biological agents also pose new challenges to clinicians.To standardize use of biological agents to treat IBD,Inflammatory Bowel Disease Quality Control Center and Inflammatory Bowel Disease Group,Chinese Society of Gastroenterolgy,Chinese Medical Association organized experts to formulate this guidance including indications,contraindications,effectiveness,screening and preventing opportunistic infections,response monitoring,issues for special population and safety.This consensus is expected to faciliate the standard use of biologics in patients with IBD in China.